Drug Repurposing Identifies Inhibitors of Oseltamivir‐Resistant Influenza Viruses
Identifieur interne : 001163 ( Istex/Curation ); précédent : 001162; suivant : 001164Drug Repurposing Identifies Inhibitors of Oseltamivir‐Resistant Influenza Viruses
Auteurs : Ju Bao [États-Unis] ; Bindumadhav Marathe [États-Unis] ; Elena A. Govorkova [États-Unis] ; Jie J. Zheng [États-Unis]Source :
- Angewandte Chemie International Edition [ 1433-7851 ] ; 2016-03-01.
Abstract
The neuraminidase (NA) inhibitor, oseltamivir, is a widely used anti‐influenza drug. However, oseltamivir‐resistant H1N1 influenza viruses carrying the H275Y NA mutation spontaneously emerged as a result of natural genetic drift and drug treatment. Because H275Y and other potential mutations may generate a future pandemic influenza strain that is oseltamivir‐resistant, alternative therapy options are needed. Herein, we show that a structure‐based computational method can be used to identify existing drugs that inhibit resistant viruses, thereby providing a first line of pharmaceutical defense against this possible scenario. We identified two drugs, nalidixic acid and dorzolamide, that potently inhibit the NA activity of oseltamivir‐resistant H1N1 viruses with the H275Y NA mutation at very low concentrations, but have no effect on wild‐type H1N1 NA even at a much higher concentration, suggesting that the oseltamivir‐resistance mutation itself caused susceptibility to these drugs.
Finding a new purpose: A structure‐based computational screen identified the FDA‐approved drugs nalidixic acid and dorzolamide as potent inhibitors of the influenza H275Y neuraminidase mutant, but not the wild‐type enzyme. H275Y is the most common drug‐resistance mutation in neuraminidase, and this screening method enables rapid identification of inhibitors for newly emerging mutations.
Url:
DOI: 10.1002/anie.201511361
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001163
Links to Exploration step
ISTEX:534D843CC45A6936048E11248C2F8D94EC7C6574Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Drug Repurposing Identifies Inhibitors of Oseltamivir‐Resistant Influenza Viruses</title><author><name sortKey="Bao, Ju" sort="Bao, Ju" uniqKey="Bao J" first="Ju" last="Bao">Ju Bao</name><affiliation wicri:level="1"><mods:affiliation>Department of Structural Biology, St. Jude Children's Research Hospital, TN, 38105, Memphis, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Structural Biology, St. Jude Children's Research Hospital, TN, 38105, Memphis</wicri:regionArea></affiliation></author><author><name sortKey="Marathe, Bindumadhav" sort="Marathe, Bindumadhav" uniqKey="Marathe B" first="Bindumadhav" last="Marathe">Bindumadhav Marathe</name><affiliation wicri:level="1"><mods:affiliation>Department of Infectious Diseases, St. Jude Children's Research Hospital, TN, 38105, Memphis, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Infectious Diseases, St. Jude Children's Research Hospital, TN, 38105, Memphis</wicri:regionArea></affiliation></author><author><name sortKey="Govorkova, Elena A" sort="Govorkova, Elena A" uniqKey="Govorkova E" first="Elena A." last="Govorkova">Elena A. Govorkova</name><affiliation wicri:level="1"><mods:affiliation>Department of Infectious Diseases, St. Jude Children's Research Hospital, TN, 38105, Memphis, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Infectious Diseases, St. Jude Children's Research Hospital, TN, 38105, Memphis</wicri:regionArea></affiliation></author><author><name sortKey="Zheng, Jie J" sort="Zheng, Jie J" uniqKey="Zheng J" first="Jie J." last="Zheng">Jie J. Zheng</name><affiliation wicri:level="1"><mods:affiliation>Department of Structural Biology, St. Jude Children's Research Hospital, 38105, Memphis, TN, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Structural Biology, St. Jude Children's Research Hospital, 38105, Memphis, TN</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Stein Eye Institute, Department of Ophthalmology, David Geffen School of Medicine at UCLA, 90095, Los Angeles, CA, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Stein Eye Institute, Department of Ophthalmology, David Geffen School of Medicine at UCLA, 90095, Los Angeles, CA</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Infectious Diseases, St. Jude Children's Research Hospital, TN, 38105, Memphis, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Infectious Diseases, St. Jude Children's Research Hospital, TN, 38105, Memphis</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>E-mail: jzheng@jsei.ucla.edu</mods:affiliation><country wicri:rule="url">États-Unis</country></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:534D843CC45A6936048E11248C2F8D94EC7C6574</idno><date when="2016" year="2016">2016</date><idno type="doi">10.1002/anie.201511361</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-J8PTGJF6-X/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001163</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001163</idno><idno type="wicri:Area/Istex/Curation">001163</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Drug Repurposing Identifies Inhibitors of Oseltamivir‐Resistant Influenza Viruses</title><author><name sortKey="Bao, Ju" sort="Bao, Ju" uniqKey="Bao J" first="Ju" last="Bao">Ju Bao</name><affiliation wicri:level="1"><mods:affiliation>Department of Structural Biology, St. Jude Children's Research Hospital, TN, 38105, Memphis, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Structural Biology, St. Jude Children's Research Hospital, TN, 38105, Memphis</wicri:regionArea></affiliation></author><author><name sortKey="Marathe, Bindumadhav" sort="Marathe, Bindumadhav" uniqKey="Marathe B" first="Bindumadhav" last="Marathe">Bindumadhav Marathe</name><affiliation wicri:level="1"><mods:affiliation>Department of Infectious Diseases, St. Jude Children's Research Hospital, TN, 38105, Memphis, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Infectious Diseases, St. Jude Children's Research Hospital, TN, 38105, Memphis</wicri:regionArea></affiliation></author><author><name sortKey="Govorkova, Elena A" sort="Govorkova, Elena A" uniqKey="Govorkova E" first="Elena A." last="Govorkova">Elena A. Govorkova</name><affiliation wicri:level="1"><mods:affiliation>Department of Infectious Diseases, St. Jude Children's Research Hospital, TN, 38105, Memphis, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Infectious Diseases, St. Jude Children's Research Hospital, TN, 38105, Memphis</wicri:regionArea></affiliation></author><author><name sortKey="Zheng, Jie J" sort="Zheng, Jie J" uniqKey="Zheng J" first="Jie J." last="Zheng">Jie J. Zheng</name><affiliation wicri:level="1"><mods:affiliation>Department of Structural Biology, St. Jude Children's Research Hospital, 38105, Memphis, TN, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Structural Biology, St. Jude Children's Research Hospital, 38105, Memphis, TN</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Stein Eye Institute, Department of Ophthalmology, David Geffen School of Medicine at UCLA, 90095, Los Angeles, CA, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Stein Eye Institute, Department of Ophthalmology, David Geffen School of Medicine at UCLA, 90095, Los Angeles, CA</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Infectious Diseases, St. Jude Children's Research Hospital, TN, 38105, Memphis, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Infectious Diseases, St. Jude Children's Research Hospital, TN, 38105, Memphis</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>E-mail: jzheng@jsei.ucla.edu</mods:affiliation><country wicri:rule="url">États-Unis</country></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Angewandte Chemie International Edition</title><title level="j" type="alt">ANGEWANDTE CHEMIE INTERNATIONAL EDITION</title><idno type="ISSN">1433-7851</idno><idno type="eISSN">1521-3773</idno><imprint><biblScope unit="vol">55</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="3438">3438</biblScope><biblScope unit="page" to="3441">3441</biblScope><biblScope unit="page-count">4</biblScope><date type="published" when="2016-03-01">2016-03-01</date></imprint><idno type="ISSN">1433-7851</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1433-7851</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The neuraminidase (NA) inhibitor, oseltamivir, is a widely used anti‐influenza drug. However, oseltamivir‐resistant H1N1 influenza viruses carrying the H275Y NA mutation spontaneously emerged as a result of natural genetic drift and drug treatment. Because H275Y and other potential mutations may generate a future pandemic influenza strain that is oseltamivir‐resistant, alternative therapy options are needed. Herein, we show that a structure‐based computational method can be used to identify existing drugs that inhibit resistant viruses, thereby providing a first line of pharmaceutical defense against this possible scenario. We identified two drugs, nalidixic acid and dorzolamide, that potently inhibit the NA activity of oseltamivir‐resistant H1N1 viruses with the H275Y NA mutation at very low concentrations, but have no effect on wild‐type H1N1 NA even at a much higher concentration, suggesting that the oseltamivir‐resistance mutation itself caused susceptibility to these drugs.</div><div type="abstract" xml:lang="en">Finding a new purpose: A structure‐based computational screen identified the FDA‐approved drugs nalidixic acid and dorzolamide as potent inhibitors of the influenza H275Y neuraminidase mutant, but not the wild‐type enzyme. H275Y is the most common drug‐resistance mutation in neuraminidase, and this screening method enables rapid identification of inhibitors for newly emerging mutations.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001163 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 001163 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:534D843CC45A6936048E11248C2F8D94EC7C6574
|texte= Drug Repurposing Identifies Inhibitors of Oseltamivir‐Resistant Influenza Viruses
}}
| This area was generated with Dilib version V0.6.34. |  |